These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 28512738)

  • 41. Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach.
    Fabris E; Merlo M; Rapezzi C; Ferrari R; Metra M; Frigerio M; Sinagra G
    Drugs; 2019 Sep; 79(14):1543-1556. PubMed ID: 31432436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Owens AT; Brozena S; Jessup M
    Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
    Yandrapalli S; Aronow WS; Mondal P; Chabbott DR
    Am J Ther; 2017; 24(2):e234-e239. PubMed ID: 27574931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential Expanded Indications for Neprilysin Inhibitors.
    Riddell E; Vader JM
    Curr Heart Fail Rep; 2017 Apr; 14(2):134-145. PubMed ID: 28281174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
    Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
    Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
    J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
    Bartell N; Frishman WH
    Cardiol Rev; 2017; 25(6):315-320. PubMed ID: 28984670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
    Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G
    Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
    Lu BN; Davis LE
    JAAPA; 2018 Jul; 31(7):35-37. PubMed ID: 29957605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.